Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results vaccine efficacy after dose 1 (and before dose 2) E

COVID-19 prophylaxis (excluding children) meta-analysis

Asano
 
NCT04568031
RCTVaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)placeboCOVID-19 prophylaxis (excluding children)NA
-/- inconclusive
Com-COV2
 
ISRCTN 27841311
RCTVaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)vaccinesCOVID-19 prophylaxis (excluding children)NA
-/- inconclusive
AstraZeneca phase 3 US (D8110C00001)
 
NCT04516746
RCTVaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)placeboCOVID-19 prophylaxis (excluding children)NA
21583/10796 safety concern
Com-COV
 
ISRCTN69254139
RCTVaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)Comirnaty (tozinameran - Pfizer/BIONTECH)COVID-19 prophylaxis (excluding children)NA
-/- inconclusive
AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety RCTVaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)controlCOVID-19 prophylaxis (excluding children)NA
12282/11962 inconclusive
ChAdOx1 phase 3 (AstraZeneca)
 
NCT04400838
RCTVaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)controlCOVID-19 prophylaxis (excluding children)some concern
5807/5829 conclusif -68%
Scotland cohort unpublished OBSVaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)controlCOVID-19 prophylaxis (excluding children)NA
-/- suggested -85%
EPIPHARE (Vaxzevria) OBSVaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)controlCOVID-19 prophylaxis (excluding children)NA
-/- safety concern
Hippisley-Cox OBSVaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)controlCOVID-19 prophylaxis (excluding children)NA
-/- safety concern
Patone OBSVaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)controlCOVID-19 prophylaxis (excluding children)NA
-/- safety concern
Simpson (ChAdOx1) OBSVaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)controlCOVID-19 prophylaxis (excluding children)NA
-/- safety concern
Bernal (PHE, 19th February 2021) OBSVaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)controlCOVID-19 prophylaxis (excluding children)NA
-/- no results
Burn (Vaxzevria) OBSVaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)controlCOVID-19 prophylaxis (excluding children)critical
-/- safety concern
Edward (Vaxzevria) OBSVaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)controlCOVID-19 prophylaxis (excluding children)critical
-/- inconclusive
Bernal unpublished OBSVaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)controlCOVID-19 prophylaxis (excluding children)NA
-/- suggested
Pottegard OBSVaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)controlCOVID-19 prophylaxis (excluding children)critical
-/- safety concern

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).